The results of the analysis of medical prescriptions and the drug consumption in patients with lymphogranulomatosis in Ukraine
uk.
DOI:
https://doi.org/10.24959/sphhcj.21.213Abstract
Aim. To analyze medical prescriptions and the structure of the drug consumption in patients with lymphogranulomatosis in Ukraine.
Materials and methods. The data of medical records (455) of patients with lymphogranulomatosis were studied. The historical, analytical-comparative, systemic, logical, hypothetical-deductive, graphical methods of scientific research, as well as clinical and economic analysis as one of the components of health technology assessment were used.
Results. It was found that, on average, the patients were in the hospital for 32 bed-days, and they received 16,835 medical prescriptions. There were 37 prescriptions per patient. The leaders in the number of prescriptions were drugs from groups L – Antineoplastic and immunomodulating agents, B – Drugs affecting the blood system and hematopoiesis, and A – Drugs affecting the digestive system and metabolism. These groups of drugs accounted for more than half of medical prescriptions (9247 or 54.93 %). The structure of prescriptions was dominated by drugs in the form of solutions or powders for their preparation (62.78 % of all prescriptions or 10569). In accordance with the II level of the ATC classification, the first three positions in the number of prescriptions were drugs used in the chemotherapy and elimination of symptoms of exacerbation of chronic pathologies. These drugs were from the following groups: L01 – Antineoplastic and immunomodulating agents (12.80 % or 2154 prescriptions), B05 – Blood substitutes and perfusion solutions (11.95 % or 2012, respectively), C01 – Drugs for the treatment of heart diseases (9.99 % or 1681, respectively). Antineoplastic prescriptions ranged from 31 (L01C D01 – Paclitaxel) to 289 (L01DB01 – Doxorubicin) ones. The most prescribed drugs were L01DB01 – Doxorubicin, AA01 – Cyclophosphamide, and L01CB01 – Etoposide. It was proven that patients with lymphogranulomatosis received an average of 8.3 prescriptions of antitumor drugs. The general indicator of the drug consumption was 23440.30 thousand UAH or 822.58 thousand US dollars, which, in terms of one patient, amounted to 51,517.14 UAH or 1807.86 US dollars. It was found that 38797,60 UAH or 1361.50 USD were spent on the effective chemotherapy and maintenance of the patient’s body, which was 8.21 and 17.1 times more than the minimum wage and living wage according to the data presented in the state budget for 2020 in Ukraine.
Conclusions. It has been found that medical prescriptions and the consumption of drugs by patients with lymphogranulomatosis reflect the nature of the therapy, namely the need for intensive courses of chemotherapy, polymorbidity of patients, as well as the severity of the pathological process. Considering the high cost of the treatment the solution to the issue of increasing the level of its availability requires a systemic solution in various directions.
Key words: clinical and economic analysis; medical prescriptions; lymphogranulomatosis; Hodgkin’s disease; antineoplastic drugs; health technology assessment.
References
Smith, E. C., Ziogas, A., Anton-Culver, H. (2012). Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer, 118 (24), 6179–6187. doi: https://doi.org/10.1002/cncr.27684.
Albreht, T., Martin-Moreno, J. M., Jelenc, M., Gorgojo, L., Harris, M. (Eds.). (2015). European Guide for Quality National Cancer Control Programme. Ljubljana, 113. Available at: https://cancercontrol.eu/archived/uploads/images/European_Guide_for_Quality_National_Cancer_Control_Programmes_web.pdf.
Diefenbach, C., Steidl, C. (2013). New strategies in Hodgkin lymphoma: better risk profiling and novel treatments. Clinical Cancer Research, 19 (11), 2797–2803. doi: https://doi.org/10.1158/1078-0432.CCR-12-3064.
Montanari, F., Diefenbach, C. (2014). Relapsed Hodgkin lymphoma: management strategies. Current Hematologic Malignancy Reports, 9 (3), 284–293. doi: https://doi.org/10.1007/s11899-014-0220-7.
Houweling, T. A. J., Kunst, A. E. (2010). Socio-economic inequalities in childhood mortality in low-and middle-income countries: a review of the international evidence. British Medical Bulletin, 93 (1), 7–26. doi: https://doi.org/10.1093/bmb/ldp048.
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M. (2017). Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15 (5), 608–638. doi: https://doi.org/10.6004/jnccn.2017.0064.
Ansell, S. M. (2020). Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 95 (8), 978–989. doi: https://doi.org/10.1002/ajh.25856.
Pepper, N. B., Oertel, M., Kittel, C., Kröger, K. J., Elsayad, K., Haverkamp, U., Eich, H. T. (2021). Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin’s lymphoma. Strahlentherapie und Onkologie, 197 (1), 56–62. doi: https://doi.org/10.1007/s00066-020-01682-0.
Sullivan, R., Kowalczyk, J. R., Agarwal, B., Ladenstein, R., Fitzgeral, E., Barr, R. et al. (2013). New policies to address the global burden of childhood cancers. The Lancet Oncology, 14 (3), 125–135. doi: https://doi.org/10.1016/S1470-2045(13)70007-X.
Schaapveld, M., Aleman, B. M. P., van Eggermond, A. M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M. et al. (2015). Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. The New England Journal of Medicine, 373 (29), 2499–2511. doi: https://doi.org/10.1056/NEJMoa1505949.
Van Nimwegen, F. A., Ntentas, G., Darby, S. C., Schaapveld, M., Hauptmann, M., Lugtenburg, P. J. et al. (2017). Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood, 129 (16), 2257–2265. doi: https://doi.org/10.1182/blood-2016-09-740332.
Vassilakopoulos, T. P., Asimakopoulos, J. V., Konstantopoulos, K., Angelopoulou, M. K. (2020). Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. Therapeutic Advances in Hematology, 11. doi: https://doi.org/10.1177/2040620720902911.
Van Leeuwen, F. E., Ng, A. K. (2016). Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology (Am Soc Hematol Educ Program.), 1, 323–330. doi: https://doi.org/10.1182/asheducation-2016.1.323.
Eyre, T. A., King, A. J., Collins, G. P. (2013). Classical Hodgkin’s lymphoma: past, present and future perspectives. British Journal of Hospital Medicine, 74 (11), 612–618. doi: https://doi.org/10.12968/hmed.2013.74.11.612.
Olszewski, A. J., Shrestha, R., Castillo, J. J. (2015). Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. Journal of Clinical Oncology, 33 (6), 625–633. doi: https://doi.org/10.1200/JCO.2014.58.7543.
Mehrzad, V., Ashrafi, F., Farrashi, A. R., Pourmarjani, R., Dehghani, M., Shahsanaei, A. (2017). Comparison of ifosfamide, carboplatin and etoposide versus etoposide, steroid, and cytarabine cisplatin as salvage chemotherapy in patients with refractory or relapsed Hodgkin’s lymphoma. Advanced Biomedical Research, 6, 30. doi: https://doi.org/10.4103/2277-9175.201687.
Nemchenko, A. S., Kosiachenko, K. L. (2011). Farmatsevtychnyi zhurnal, 5, 50-54.
Piniazhko, O. B., Zaliska, O. M. (2015). Sotsialna farmatsiia v okhoroni zdorovia, 1 (2), 44-54. doi: https://doi.org/10.24959/sphhcj.15.18.
Blank, O., von Tresckow, B., Monsef, I., Specht, L., Engert, A., Skoetz, N. (2017). Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. The Cochrane Database of Systematic Reviews, 4 (4). doi: https://doi.org/10.1002/14651858.CD007110.pub3.
Liu, W. R., Shipp, M. A. (2017). Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood, 130 (21), 2265–2270. doi: https://doi.org/10.1182/blood-2017-06-781989.
Djalalov, S., Djalalova, D., Krahn, M., Matveev, N., Hoch, J. S. (2019). Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View. Value in Health Regional, 19, 138–144. doi: https://doi.org/10.1016/j.vhri.2019.04.008.
Jang, S., Chae, Y. K., Haddad, T., Majhail, N. S. (2010). Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Research and Treatment, 121 (2), 273–279. doi: https://doi.org/10.1007/s10549-010-0870-7.
Hall, P. S., Hulme, C., McCabe, C., Oluboyede, Y., Round, J., Cameron, D. A. (2011). Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. PharmacoEconomics, 29 (5), 415–432. doi: https://doi.org/10.2165/11588340-000000000-00000.
Valachis, A., Polyzos, N. P., Nearchou, A., Lind, P., Mauri, D. (2012). Financial relationships in economic analyses of targeted therapies in oncology. Journal of Clinical Oncology, 30 (12), 1316–1320. doi: https://doi.org/10.1200/JCO.2011.38.6078.
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M. et al. (2017). Hodgkin Lymphoma Version 1. 2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15 (5), 608–638. doi: https://doi.org/10.6004/jnccn.2017.0064.
Blank, O., von Tresckow, B., Monsef, I., Specht, L., Engert, A., Skoetz, N. (2017). Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. The Cochrane Database of Systematic Reviews, 4 (4). doi: https://doi.org/10.1002/14651858.CD007110.pub3.
Liu, W. R., Shipp, M. A. (2017). Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood, 130 (21), 2265–2270. doi: https://doi.org/10.1182/blood-2017-06-781989.
Wein, F., Weniger, M. A., Höing, B., Arnolds, J., Hüttmann, A., Hansmann, M.-L. (2017). Complex immune evasion Strategies in classical Hodgkin lymphoma. Cancer Immunology Research, 5 (12), 1122–1132. doi: https://doi.org/10.1158/2326-6066.CIR-17-0325.
Rak v Ukraini, 2018-2019. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. (2020). Biuleten Natsionalnoho kantser-reiestru Ukrainy, 21.
Fang, J.-Q. (Ed.). (2017). Handbook of Medical Statistics. China: Sun Yat-Sen University, 852. doi: https://doi.org/10.1142/10259.
Chetyrkin, E. M. (2010). Statisticheskie metody prohnozirovaniia. Moscow: Statistika, 199.
Zakon Ukrainy vid 14.11.2019 No. 294-IX “Pro Derzhavnyi biudzhet Ukrainy na 2020 rik”. zakon.rada.gov.ua. Available at: https://zakon.rada.gov.ua/laws/show/294-20#Text.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
